James Randolph Hillard

Chairman at Phase 2 Discovery, Inc.

Health Technology

Consumer Services

Profile

James Randolph Hillard, MD is President and Chairman of the Board of Directors for Phase 2 Discovery, Inc. He is President and Chief Executive Officer of UC Physicians, Inc. He is Chairman of the Department of Psychiatry at University of Cincinnati College of Medicine.
He is a Director for Alliance Health Care.

James Randolph Hillard active positions

Companies	Position	Start
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Chairman	-
University of Cincinnati (Ohio)	Corporate Officer/Principal	-

All active positions of James Randolph Hillard

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of James Randolph Hillard's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Health Technology